The first two Catalyst HD™ systems have been sold to a customer in North America. As part of the configuration also a Sentinel System for advanced 4D imaging has been ordered.
The Catalyst HD ™ systems will be fully equipped with the software packages for patient positioning, motion monitoring while treatment and respiratory gating. The installation is scheduled for the second quarter 2014.
Catalyst HD ™ is based on the patented C-RAD technology. With a unique arrangement of multiple 3D cameras and newly developed software, the system is convincing with superior performance for all treatments where couch rotations are applied.
All interfaces for respiratory gating and for treatment couch control, will be compatible and used with the Catalyst HD ™ . Existing software modules for Patient Setup and Positioning, Motion Monitoring during treatment and Respiratory Gating are adopted to the new system.
Stereotactic radiosurgery is a form of radiation therapy where the focused x-ray beam is delivered with very high accuracy into a small volume within the body. Therewith tumor tissue can be treated efficiently with minimizing the dose delivered to healthy tissue around the tumor. This treatment technique is especially used for head and neck treatments.
Tim Thurn, CEO of C-RAD AB:
“I am very satisfied with the positive market response to the newly released Catalyst HD system. Catalyst HD is tailored to fulfill the high demands for patient tracking in the fast growing market of advanced radiation therapy. With the results we achieved in 2013 C-RAD is starting optimistic into the new year.”
About C-RAD
C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 24 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company’s first product, the C-RAD Sentinel TM, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has acquired 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier.
For more information on C-RAD, please visit www.c-rad.com .
For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666931, E-mail investors@c-rad.com
